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The genetic basis of variation in the progression of primary tauopathies has not been 
determined. Here, we used a genome-wide association study (GWAS) to identify genetic 
determinants of survival in progressive supranuclear palsy (PSP). 
Methods 
Data were collected and analysed between 1st August 2016 and 1st February 2020. In stage 
one, we collected pathological and clinical-criteria diagnosed PSP cases from two separate 
cohorts (2011 PSP GWAS cohort cases from the Mayo Clinic and Munich brain banks; UCL 
PSP cohort cases from UK brain banks and the PROSPECT study). Cases were included if they 
had clinical data available on sex, age at motor symptom onset, disease duration (from 
motor symptom onset to death) and PSP phenotype (with reference to the 2017 Movement 
Disorder Society criteria). Genotype data from these cases were used to conduct a survival 
GWAS using a Cox-proportional hazards model. In stage two, replication data from 
additional Mayo Clinic brain bank cases, which were obtained after the 2011 PSP GWAS, 
were used for a pooled analysis. We assessed the eQTL profile of variants which passed 
genome-wide significance in our GWAS using the FUMA platform, and conducted 
colocalisation analyses using the eQTLGen and PsychENCODE datasets. 
Findings 
Data were available for 1,001 PSP cases of white European ancestry in stage one. We found 
a genome-wide significant association with survival at chromosome 12 (lead SNP: rs2242367 
– p=7.5x10ˉ¹⁰; hazard ratio (95% confidence interval)=1.42 (1.22-1.67)). In stage two, the 
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addition of 238 cases resulted in significant pooled association statistics for rs2242367 
(n=1,239; p=1.3x10ˉ¹⁰; hazard ratio (95% confidence interval)=1.37 (1.25-1.51). An eQTL 
database screen revealed that rs2242367 is associated with increased expression of LRRK2 
and long intergenic non-coding (lnc) RNAs, LINC02555 and AC079630.4, in whole blood. 
Although we did not detect a colocalisation signal for LRRK2, analysis of the PSP survival 
signal and eQTLs for LINC02555 in the eQTLGen blood dataset revealed a posterior 
probability of hypothesis 4 (PP4) of 0.77, suggesting colocalisation due to a single shared 
causal variant.  
Interpretation 
Genetic variation at the LRRK2 locus was associated with survival in PSP. The mechanism of 
this association may be through a lncRNA-regulated effect on LRRK2 expression as 
LINC02555 has previously been shown to regulate LRRK2 expression. LRRK2 has been 
associated with sporadic and familial forms of Parkinson’s disease, and our finding suggests 
a genetic overlap with PSP. Further functional studies will be important to assess the 
potential of LRRK2 modulation as a disease-modifying therapy for PSP and related 
tauopathies. 
Funding 









Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative tauopathy. 
In the classical form, PSP-Richardson syndrome (PSP-RS), patients develop imbalance and 
frequent falls, bulbar failure and dementia, and have a mean survival of 6.9 years from 
symptom onset.¹ More recently defined PSP subtypes, such as PSP-Parkinsonism (PSP-P) and 
PSP-Progressive Gait Freezing (PSP-PGF), are associated with a slower rate of 
progression.² We have shown that the PSP phenotype is modified by variation at the 
TRIM11/17 locus.³ Additionally, certain clinical features, such as early dysphagia and 
cognitive symptoms, have been shown to predict a faster rate of progression.⁴ 
The pathology of PSP involves the deposition of insoluble hyperphosphorylated tau in 
neurons and astrocytes in sub-cortical and cortical brain regions. Recent work in animal 
models has shown that PSP-tau pathology is transmissible. Extracts from human PSP brain, 
inoculated into mouse brain, lead to PSP-type pathology in the recipient which replicates 
the morphology and immunohistochemical features of the human tauopathy.⁵ Clinical 
disease progression relates to the sequential involvement of brain areas and systems. This 
may relate to different susceptibility and resistance of neurons, and cell to cell spread of 
pathology.⁶ 
Genome-wide studies in neurodegeneration have focused on case-control status, which 
have provided powerful insights into the aetiology of neurodegenerative disease. In PSP, 
common genetic variants have been associated with PSP risk.⁷¯⁹ However, therapeutic 
efforts focus on developing therapies which slow or halt disease progression, thus 
improving survival following a clinical diagnosis. Previous clinical trials targeting microtubule 
dysfunction and tau hyperphosphorylation have shown no benefit in slowing disease 
progression in PSP patients.¹⁰,¹¹ Current clinical trials in both PSP and Alzheimer’s disease 
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(AD) patients aim to prevent cell to cell spread of tau by using neutralising antibodies 
against tau in the extracellular space.¹² 
The genetic determinants of clinical disease progression and survival for neurodegenerative 
diseases are largely unexplored and are likely to provide important biological insights that 
may lead to new therapeutic approaches. A recent disease progression genome-wide 
association study (GWAS) in Huntington’s disease identified a functional variant in MSH3, a 
DNA-repair gene, associated with disease progression based on longitudinal change in 
motor, cognitive and imaging measures.¹³  
Here, we have conducted a GWAS using a Cox-proportional hazards model to identify 
genetic determinants of survival (from motor symptom onset to death) in PSP cases of white 
















Research in context 
Evidence before this study: We searched PubMed for articles on progressive 
supranuclear palsy with no language restrictions from database inception up to July 1, 
2020, using the following terms: “progressive supranuclear palsy AND genetics”, “disease 
progression OR survival”, focusing on studies that reported survival or clinical disease 
progression. No studies were found that had investigated the genetic determinants of PSP 
survival. However, of note, we have previously shown that PSP phenotype is associated 
with the rate of clinical disease progression and so we included phenotype as a covariate 
in our survival GWAS model.  
Added value of this study: To our knowledge, this is the first survival GWAS of a primary 
tauopathy. Our study provides important evidence for the role of the LRRK2 locus in 
modifying survival in PSP, and this association appears to be independent of the LRRK2 
risk signal previously associated with Parkinson’s disease. The results of our eQTL 
database screen and colocalisation analyses highlight the potential interaction between 
non-coding RNA and gene expression, and the impact of this on the progression of 
neurodegenerative diseases. 
Implications of all the evidence available: Our study provides evidence for an overlap in 
the genetic aetiology of PSP and Parkinson’s disease. These findings pave the way for 
further functional studies on the impact of LRRK2 on tau pathology. LRRK2 modulation is 
currently being trialled as a disease-modifying therapy in Parkinson’s disease patients, 
and our study highlights the potential of this approach having a therapeutic role in 
tauopathies. In the meantime, further genetic replication of this finding may provide 
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evidence for using LRRK2 locus genotype for predicting progression in clinical practice, 
and the stratification of PSP patients for future clinical trials.   
 
Methods 
Study design and participants 
Data were collected and analysed between 1st August 2016 and 1st February 2020. In stage 
one, cases with either a neuropathological or clinical diagnosis of PSP were identified from 
two separate cohorts: 2011 PSP GWAS cohort cases from the Mayo Clinic and Munich brain 
banks (pathologically diagnosed); UCL PSP cohort cases from UK brain banks (pathologically 
diagnosed) and the Progressive Supranuclear Palsy-Cortico-Basal Syndrome-Multiple System 
Atrophy (PROSPECT) study (clinically diagnosed) (Supplementary Table 1, p. 2). Local ethics 
committees at each of the brain banks approved this work and each patient had previously 
provided written informed consent for their clinical data and DNA to be used in research 
projects, including genetic studies. The UCL PSP cohort included clinically diagnosed cases 
from the PROSPECT study, a UK-wide longitudinal study of patients with atypical 
parkinsonian syndromes.² These patients had provided written informed consent for their 
clinical data and DNA to be used in research projects, including genetic studies. A subset of 
deceased PROSPECT study PSP cases had provided separate written informed consent for 
post-mortem neuropathological confirmation of diagnosis at Queen Square (diagnosis by 
Z.J., J.L.H. and T.R.) and Cambridge (diagnosis by K.S.J.A.) brain banks.  
In stage two, cases with a neuropathological diagnosis of PSP (diagnosis by D.W.D) were 
identified from the Mayo Clinic brain bank. Of note, these additional cases had entered the 
brain bank after publication of the 2011 PSP case-control GWAS,⁷ and had provided written 
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informed consent for their clinical data and DNA to be used in research projects, including 
genetic studies. 
In both stage one and two, all PSP cases were considered for inclusion in this study, 
provided they had an adequate depth of phenotype data available for clinical 
characterisation, and passed genotype quality control steps (see below). 
 
Procedures 
In stage one and two, all PSP cases were assigned a Movement Disorder Society (MDS) PSP 
diagnostic criteria phenotype based on clinical features that were present in the first three 
years from motor symptom onset, using consensus criteria on application of the diagnostic 
criteria.¹⁴,¹⁵ Cases were subsequently stratified into PSP-RS and non-PSP-RS groups, where 
non-PSP-RS consisted of PSP-parkinsonism and PSP-progressive gait freezing phenotypes. 
For pathologically diagnosed brain bank cases, this approach was applied retrospectively 
using detailed case notes (stage one cases by E.J., D.W.D., G.R. and G.U.H.; stage two cases 
by S.K. and D.W.D.). For clinically diagnosed PROSPECT study cases included in stage one, 
patients were assigned a baseline PSP phenotype on entry to the study by E.J. using the 
same criteria as above. Of note, all included PROSPECT study PSP cases were at least three 
years into their disease course (from motor symptom onset) and fulfilled at least “possible” 
diagnostic criteria for a PSP phenotype.  
In addition, the following clinical data was collected for cases in stage one and two: sex; age 
at motor symptom onset; disease duration from motor symptom onset to death, or motor 
symptom onset to date of censoring (01/12/2019) for living PROSPECT study PSP cases. 
Motor symptom onset was defined as the point at which motor dysfunction was persistent 
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and affected normal activities of daily living. Cases were excluded from the study if there 
was inadequate clinical data to accurately assign both PSP phenotype and disease duration. 
In stage one, cases underwent genotyping using the Illumina NeuroChip (UCL cohort cases) 
or the Illumina Human 660W-Quad Infinium chip (2011 GWAS cohort cases).⁷,¹⁶ The two 
datasets were then merged and imputed as one common dataset. In stage two, lead SNPs of 
all genome-wide significant loci from the stage one GWAS were genotyped using a TaqMan 
assay. A detailed description of the genotype data and imputation methods used can be 
found in the Supplementary Material, pp. 3-4.   
As most GWAS loci are thought to operate by regulating gene expression,¹⁷,¹⁸ we screened 
all significant SNPs from our GWAS for expression quantitative trait loci (eQTL) signals using 
Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) 
(https://fuma.ctglab.nl).¹⁹ SNPs were defined as eQTLs if their false discovery rate (FDR) 
corrected p-value was significant (p<0.05). A detailed description of FUMA’s eQTL data 
sources are available at https://fuma.ctglab.nl/tutorial#snp2gene. Additionally, the North 
American Brain Expression Consortium (NABEC) eQTL dataset (213 human frontal cortex 
samples) was analysed (dbGaP Study Accession: phs001300.v1.p1).  
 
We applied coloc²⁰ (version 3.2.1) to evaluate the probability of colocalisation between two 
traits, which in this case were PSP survival and regulation of gene expression via eQTLs. We 
used cis-eQTLs from eQTLGen²¹ and PsychENCODE²² datasets, which represent the largest 
human blood and brain expression datasets, respectively (eQTLGen, sample size = 31,684 
individuals; PsychENCODE, sample size = 1,387 individuals). Loci with a posterior probability 
of H4 (PP4) ≥ 0.75 were considered colocalised due to a single shared causal variant. A 




A subset (n=140) of PROSPECT study PSP cases of white European ancestry underwent 
whole-genome sequencing (WGS) at Uniformed Services University of Health Sciences 
(Bethesda, MD, USA). These samples represent all of the PROSPECT study PSP cases that we 
had recruited as of 01/12/2017 when samples were sent for WGS. A detailed description of 
the methods used can be found in the Supplementary Material, pp. 4-5. 
 
Statistical analysis 
In stage one we began by assessing the association between known PSP genetic risk and 
phenotype variants³,⁷ˉ⁹ and survival using a Cox-proportional hazards model that adjusted 
for sex, age at motor symptom onset and the first three genetic principal components (PCs) 
derived from PCA. We then conducted a survival GWAS using the same model, with the 
addition of PSP phenotype (PSP-RS or non-PSP-RS) as a covariate based on the results of the 
initial analysis. Of note, the model was applied to each SNP in our dataset one at a time, 
resulting in each SNP having a hazard ratio, 95% confidence interval and associated p-value. 
The GWAS was repeated for only pathologically diagnosed cases to assess for differences in 
association statistics, which may be due to the inclusion of clinically diagnosed cases that 
were incorrectly diagnosed with PSP in the original stage one GWAS. We used Akaike 
Information Criterion (AIC) analyses²³ to consider the use of additional covariates (study site 
and further genetic PCs) by assessing the goodness of fit of the model with and without 
each variable. All reported significant SNPs had a Cox.zph p-value >0.05, indicating that the 
model adhered to the assumption of proportional hazards. Code for the Cox-proportional 
hazards survival model are available on GitHub (https://github.com/huw-morris-lab/PSP-
survival-gwas). These analyses (using the ‘survival’ and ‘survminer’ packages) and the 
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creation of Figure 1a, 2 and 3 were conducted in R (version 3.3.2). Figure 1b was created 
using LocusZoom (version 0.10). The Bonferroni-corrected threshold for genome-wide 
significance in stage one was set at p<1.0x10ˉ⁸. To assess for the presence of more than one 
independent signal within a genome-wide significant locus, we re-ran the stage one GWAS 
as a conditional analysis, with the lead SNP genotype included as a covariate in the model. 
For additional cases in stage two, the same Cox-proportional hazards survival model was 
applied to genotype results of the lead SNP from the stage one GWAS, with significance set 
at p<0.05. The genotype results of this SNP for stage one and stage two cases were then 
pooled and analysed to obtain a more accurate estimate of the effect size of the lead SNP, 
accounting for all of the cases included in this study. 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding authors had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
 
Results 
A total of 1,033 cases were considered for inclusion in stage one. Following post-imputation 
data quality control, 4,817,946 common (minor allele frequency ≥1%) SNPs were used for 
analyses. 32 cases were excluded due to either insufficient clinical data or failing genotype 
data quality control, including one case that was found to have a previously described MAPT 
L284R mutation.²⁴ This left 1,001 PSP cases of white European ancestry (confirmed by 
genetic PCA) for analyses, derived from two cohorts, with pathological confirmation of PSP 
achieved in 100% of deceased cases that had undergone post-mortem examination (n=841) 
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(Supplementary Table 1, p. 2). 895/1001 (89.4%) of our whole cohort were deceased at the 
date of censoring (Table 1). 
 
Table 1: Clinical characteristics of stage one PSP survival GWAS cases and stage two 
replication cases  
  Stage one Stage two 









No. of subjects 720 281 395 182 325 99 220 18 
% male subjects 59.2 51.2 62.3 51.1 55.4 51.5 52.7 55.6 



















No. of cases 
deceased at the 







































PSP-RS = PSP-Richardson syndrome, non-PSP-RS = Combined PSP-parkinsonism and PSP-
progressive gait freezing cases. SD = standard deviation (SD). * = Date of censoring was 
01/12/2019.  
 
Using a Cox-proportional hazards survival model, we found no association between survival 
and all of the known PSP risk variants (p>0.05) after adjusting for sex, age at motor 
symptom onset and the first three genetic PCs to account for population substructure 
(Supplementary Table 2, p. 6). There was an association between the known PSP phenotype 
TRIM11/17 locus (rs564309) and survival – p = 0.02, hazard ratio (95% confidence interval) = 
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0.88 (0.80-0.97), but this signal was attenuated when phenotype was added in as a binary 
(PSP-RS or non-PSP-RS) covariate. We then conducted a survival GWAS using sex, age at 
motor symptom onset, PSP phenotype and the first three genetic PCs as covariates. The 
genomic inflation factor (lambda) was 1.05, suggesting that there was no confounding by 
population stratification. In the whole-cohort analysis we found a genome-wide significant 
association signal at chromosome 12 (Figure 1a), with eight SNPs reaching the significance 
threshold. The lead SNP at this locus, rs2242367 (GRCh37 chr12:40413698), was associated 
with PSP survival – p = 7.5x10ˉ¹⁰, hazard ratio (95% confidence interval) = 1.42 (1.22-1.67) 
(Figure 1b), with the minor allele associated with worsening survival – Kaplan-Meier survival 
analysis log-rank test p = 5.5x10ˉ⁴ (Figure 2). A summary of sub-genome-wide significant 
signals can be found in Supplementary Table 3, pp. 7-9. The association between rs2242367 
and survival was observed in each separate cohort (Table 2). A conditional analysis that 
adjusted for rs2242367 genotype did not reveal other independent association signals. We 
referred to the summary statistics of previous GWAS and found that rs2242367 was not 
associated with PSP risk or PSP phenotype (Supplementary Table 4, p. 10). Our AIC analyses 
justified the approach of not adjusting for study site and using only the first three PCs as 
covariates to avoid overfitting (Supplementary Material, p. 10). To ensure that our genetic 
signal was not being driven by non-PSP patients in our small subset of clinically diagnosed 
cases, we repeated the stage one analysis using only pathologically diagnosed PSP cases 
(n=841). Reassuringly, this resulted in rs2242367 remaining as our lead SNP with similar 
association statistics (p = 6.9x10ˉ⁸, hazard ratio (95% confidence interval) = 1.37 (1.22-1.54)) 




Figure 1: Manhattan and regional association plots, with supporting eQTL data, 
highlighting LRRK2 association with PSP survival 
16 
 
a, Manhattan plot of PSP survival GWAS, highlighting a genome-wide significant signal at 
chromosome 12. The red line indicates the Bonferroni-corrected threshold for genome-wide 
significance (p<1.0x10ˉ⁸). b, Regional association plot of PSP survival GWAS, identifying 
rs2242367 as the lead SNP with associated significant results from an eQTL database screen. 
r² = r² linkage disequilibrium. SNP positions, recombination rates and gene boundaries are 
based on GRCh37/hg19. 
Figure 2: Kaplan-Meier survival curve for rs2242367 
Kaplan-Meier survival curve highlighting differences in survival in PSP, comparing cases 
carrying rs2242367 GG genotype, ‘0’ risk allele (red line) AG genotype, ‘1’ risk allele (green 
line) and AA genotype, ‘2’ risk alleles (blue line). Analysis of rs2242367 under an additive 
model showed that carrying an A allele was significantly associated with decreased survival 
(log-rank test p = 5.5x10ˉ⁴). 
 
In stage two, an additional 415 pathologically diagnosed PSP cases of white European 
ancestry from the Mayo Clinic brain bank were genotyped for rs2242367 using a TaqMan 
assay. 238/415 (57%) of these cases had adequate phenotype data to accurately assign a 
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PSP phenotype and disease duration using the same methods as in stage one and were 
therefore analysed (Table 1). No evidence of deviation from the Hardy-Weinberg 
equilibrium was observed. Using the same Cox-proportional hazards survival model as in 
stage one, we found that rs2242367 was associated with PSP survival – p = 0.049, hazard 
ratio (95% confidence interval) 1.22 (1.00-1.48). There appeared to be an additive allele / 
survival relationship in deceased cases across all three cohorts, and in both PSP-RS and non-
PSP-RS cases (Table 2).  
A pooled Cox-proportional hazards survival analysis of rs2242367 genotype using all stage 
one and stage two cases (n=1,239) was significant – p = 1.3x10ˉ¹⁰, hazard ratio (95% 
















Table 2: rs2242367 association statistics and impact of genotype on disease duration in 
deceased PSP cases 




















No. of subjects 395 182 325 99 220 18 940 299 
Mean disease duration in 
deceased cases with 


















Mean disease duration in 
deceased cases with 


















Mean disease duration in 
deceased cases with 


















rs2242367 risk allele 
frequency*, % 
23.5 28.0 24.9 26.3 25.2 25.0 24.4 27.3 






1.22 (1.00-1.48) 1.37 (1.25-1.51) 
 
rs2242367 p-value 1.4x10ˉ⁶ 6.7x10ˉ⁵ 0.049 1.3x10ˉ¹⁰ 
 
rs2242367 major allele = G, rs2242367 minor allele = A, SD = standard deviation, 95% CI = 
95% confidence interval, PSP-RS = PSP-Richardson syndrome, non-PSP-RS = Combined PSP-
parkinsonism and PSP-progressive gait freezing cases. * = rs2242367 risk allele frequency in 
7,692 reference controls of non-Finnish white European ancestry was 28.2%, taken from 
https://gnomad.broadinstitute.org on 10/01/2020. 
 
There are no coding variants in linkage disequilibrium (LD) with the lead SNP rs2242367 as 
defined by the region encompassed by variants with an r²>0.3 (Supplementary Figure 1, p. 
14). We mined available eQTL datasets to better understand the molecular mechanisms 
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underlying PSP survival. Using FUMA, we found that rs2242367, and associated SNPs in high 
r2 LD (>0.80), were significant eQTLs for LRRK2 expression in whole blood and oesophagus in 
the eQTLGen and GTEXv8 datasets respectively (Figure 1b). rs2242367 was also an eQTL for 
the long intergenic non-coding (lnc) RNAs, LINC02555 (ENSG00000260943, p=3.3x10ˉ³¹⁰) 
and AC079630.4 (ENSG00000223914, p=5.8x10ˉ²²), in the eQTLGen whole blood dataset. Of 
note, the minor allele at rs2242367, which we show to be associated with reduced survival 
in PSP, was associated with increased expression of LRRK2, LINC02555 and AC079630.4. 
Although FUMA’s eQTL database screen did not highlight any significant eQTL signals in 
brain, we did note that rs2242367 and its surrounding significant SNPs reached nominal 
significance (2.1x10ˉ⁵ – 9.1x10ˉ⁵) in GTEx version 8 for impacting on the expression of LRRK2 
in the caudate, and AC079630.4 in the pituitary. Additionally, we interrogated the NABEC 
brain dataset and found no significant eQTL signals associated with rs2242367.  
 
Given the findings from the eQTL database screen, we performed colocalisation analyses to 
evaluate the probability that the same causal SNP was responsible for modifying PSP 
survival and modulating gene expression. eQTLs were obtained from eQTLGen and 
PsychENCODE, the largest available human blood and brain eQTL datasets, respectively. Our 
analyses found no colocalisation signals between PSP survival and LRRK2 expression. 
However, we identified a colocalisation of signals (PP4 = 0.77) between PSP survival loci and 
blood-derived eQTLs regulating the expression of the lncRNA, LINC02555 (Figure 3) 
(Supplementary Table 5, pp. 11-12). No significant associations between PSP survival loci 




Figure 3: Colocalisation of blood-derived eQTLs regulating LINC02555 expression and 
overlapping PSP survival loci 
Plot of -log10(p-values) for the region surrounding LINC02555 shows colocalisation of blood-
derived LINC02555 eQTLs (top panel) and PSP survival signal (bottom panel) (PP4 = 0.77). In 
the top panel: black dots = eQTL p-values; grey dots = PSP survival p-values. The black bar in 







A subset of the UCL cohort cases (n=140) underwent WGS. In these cases, the genotypes of 
our eight genome-wide significant SNPs (rs2242367, rs1542594, rs2128276, rs11174918, 
rs10878029, rs7967822, rs11564279 and rs1871895) had 100% concordance between WGS 
and chip-based imputed datasets. We applied the Cox-proportional hazards survival model 
on WGS variants with a minor allele frequency ≥0.1% in our region of interest (GRCh38 
chr12:39225001-41369277) and identified 214 variants with a stronger association signal 
than rs2242367 (p<0.01). All of these were non-coding variants in LD with rs2242367 
(r²=0.30-0.35, D’=0.96-1.0) and were eQTLs (p<1.0x10ˉ²⁰) for increasing LRRK2, LINC02555 
and AC079630.4 expression in whole blood in the eQTLGen dataset. None of the variants 
were significant eQTLs for LRRK2, LINC02555 or AC079630.4 expression in brain (FDR-
corrected p>0.05).  
  
Discussion 
We have shown that variation at the LRRK2 locus is a genetic determinant of survival in the 
primary tauopathy, PSP. This signal was shown in each of our cohorts (total n = 1,239), 
suggesting that the finding is robust. A particular strength of this study was the fact that our 
outcome measure was disease duration that captures the entire clinical disease course, 
from motor symptom onset to death. This is in contrast to other neurodegenerative disease 
progression GWAS that have used longitudinal rate of change in clinical rating scale 
scores,¹³,²⁵ which only capture specific time points in the disease course, and are subject to 
inter- and intra-rater variability. Diagnostic accuracy was not a limitation in this study as the 
majority of cases we included had pathological confirmation of PSP pathology at post-
mortem. Previously we have shown that a clinical diagnosis of PSP using the MDS diagnostic 
criteria is strongly predictive of underlying PSP pathology.² Nevertheless, our sub-analysis of 
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only pathological cases further supports our findings, and does not suggest that there was 
significant inclusion of clinically diagnosed non-PSP cases in the whole-cohort analysis. 
Assignment of motor symptom onset in our study was made blinded to the genotype results 
using a standard definition.  
 
LRRK2 is an established major risk factor for Parkinson’s disease (PD) with common and rare 
(G2019S) variants associated with disease.²⁶ The lead SNP from our PSP survival GWAS, 
rs2242367, lies within intron 3 of SLC2A13, 190Kb from the common LRRK2 risk SNP for PD, 
rs76904798,²⁶ which has also been nominally associated (p=3.0x10ˉ⁴) with the rate of motor 
progression of PD.²⁵ The two variants are in low r² LD in non-Finnish white European 
populations, but with a high D’ (r²=0.05, D’=0.90) (LDlink v3.8). Of note, rs2242367 had 
association statistics that approached genome-wide significance in the most recent PD case-
control GWAS (p = 1.6x10ˉ⁷, odds ratio (95% confidence interval) = 0.94 (0.92-0.96)).²⁶ The 
allele frequency of rs2242367 is 28% while the allele frequency of rs76904798 is 13% 
(GnomAD v2.1.1), and so the LRRK2 PD risk SNP may define a sub-haplotype of the ancestral 
PSP survival haplotype. This region also contains association signals for two 
immune/inflammatory diseases, Crohn’s disease²⁷ and leprosy.²⁸ None of the risk SNPs at 
this locus identified through case-control GWAS for PD, Crohn’s disease and leprosy had 
significant association statistics in the PSP survival GWAS (Supplementary Table 6, p. 13). 
Our analyses suggest that the genetic signal at the LRRK2 locus associated with PSP survival 
is distinct from the LRRK2 locus signals identified in the PD case-control GWAS, although the 
high D’ LD statistics between rs2242367 and 76904798 mean that we cannot rule out the 
possibility that the two signals are related. However, a conditional analysis on our lead SNP 
did not identify any independent association signals. A formal genetic correlation analysis of 
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the PSP survival and PD risk GWAS results will help to explore the potential genetic overlap 
between these traits. Additionally, analysis of our subset of cases that had WGS data 
available suggests that the association signal at rs2242367 may be part of a haplotype block, 
paving the way for better-powered studies using WGS datasets to clarify this. 
 
LRRK2 is expressed in multiple human tissues including brain and whole blood. In brain, it is 
expressed ubiquitously across all regions and is found in neurons, astrocytes, microglia and 
oligodendroglia.²⁹ Pathogenic mutations in LRRK2 lead to phosphorylation of a subset of Rab 
proteins which have important roles in the formation and trafficking of intracellular 
vesicles.³⁰ This in turn may affect proteostasis and the inflammatory response, both of 
which may be important in mediating disease progression in PSP.³¹  
 
There is also an established link between LRRK2 and tau pathology, which was reported in 
chromosome 12 linked PD families before the identification of the LRRK2 gene.³² In rare 
cases, LRRK2 mutations have been identified in patients with PSP-tau pathology at post-
mortem.³³  The link between LRRK2 and tau pathology has previously been explored in cell 
and animal models, identifying dysregulation of actin and mitochondrial dynamics, and the 
impairment of tau degradation via the proteasome.³⁴ˉ³⁶ Most recently, a whole-genome 
CRISPR screen has provided functional support for our genetic findings by identifying LRRK2-
regulated endocytosis as a major mechanism for extracellular tau uptake by human 
neurons.³⁷ 
 
In our eQTL database screen, the lead SNP, rs2242367, was shown to be an eQTL for 
regulating LRRK2 expression in whole blood. Of note, when referring to the two brain-
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derived regulatory tracks (University of California, San Francisco brain DNA methylation; 
University of Massachusetts Medical School brain histone) in the University of California, 
Santa Cruz genome browser (https://genome.ucsc.edu/), we found that rs2242367 lies in a 
region that is methylated and may therefore impact on the regulation of gene expression. 
However, our colocalisation analyses using the largest brain and blood-derived eQTL 
datasets demonstrated that LRRK2 eQTLs and our PSP survival signal do not colocalise, but 
rather represent two independent causal variants (PP3 > 0.99 in both eQTL datasets). 
Instead, we identified a colocalisation signal for the lncRNA, LINC02555, which is <500Kb 
proximal to LRRK2. In GTEx version 8, LINC02555 was shown to have low levels of expression 
in bulk RNA analysis from brain 
(https://www.gtexportal.org/home/gene/ENSG00000260943). However, lncRNAs are 
known to be less expressed than mRNAs with highly variable cell-specific expression³⁸ and 
so may be hard to detect through bulk RNA sequencing. Nevertheless, it is well established 
that some lncRNAs control the expression of LRRK2,³⁹ and silencing of LINC02555 in 
papillary thyroid carcinoma cells has been shown to decrease LRRK2 expression and 
enhance autophagy in association with reduced tumour formation.⁴⁰ Therefore, lncRNAs 
may be important in regulating state-specific, regional or cell-type-specific gene expression.  
The strongest evidence for the effect on expression is reported from blood rather than bulk 
RNA analysis from brain. This may relate to the cell types present and sample size 
differences in blood and brain expression datasets. In the PsychENCODE bulk RNA dataset, 
most of the power for detecting eQTL signals in the brain comes from astrocytes and 




Alternatively, the predominant effect on expression in blood may relate to peripheral 
immune response-driven neuroinflammation or be due to a specific effect in 
monocyte/microglial lineage cells.⁴¹ Increased LRRK2 expression may result in a reactive 
microglia-induced pro-inflammatory state which drives ongoing accumulation of misfolded 
tau protein and clinical disease progression.⁴²,⁴³ This hypothesis is supported by in vivo 
positron emission tomography evidence of a pattern of microglial activation which 
correlates with disease severity in PSP,⁴⁴,⁴⁵ and co-localises with the tauopathy of PSP and 
other forms of frontotemporal lobar degeneration tauopathy.⁴⁶ In mouse models, microglial 
inflammatory responses are attenuated by LRRK2 inhibition⁴³ and this strategy is currently 
under investigation in PD as a disease-modifying therapy 
(https://clinicaltrials.gov/ct2/show/NCT03710707?term=dnl201&draw=1&rank=1).  
We acknowledge potential limitations of the study. Firstly, our stage one and stage two 
cohorts were not independent as they included cases recruited at the same centre. 
Secondly, our approach of merging different chip-based genetic datasets prior to imputation 
will reduce, albeit to a small extent, the total number of SNPs available for analysis post-
imputation,⁴⁷ with the Illumina NeuroChip having less dense genome coverage in 
comparison to the Illumina Human 660W-Quad Infinium chip. While this does not invalidate 
our primary findings, it may have led to us missing out on the identification of other signals. 
We believe that future large-scale analyses of WGS data is the most effective way of 
replicating our findings, and discovering other loci associated with PSP survival. Thirdly, as 
we have shown, bulk RNA analysis in brain is relatively underpowered to detect eQTL 
signals. In addition, we are limited in our ability to detect cell-specific effects on gene 
expression. The advent of expression analysis in defined brain cell subpopulations will help 




Future studies on the LRRK2 locus as a potential genetic determinant of disease progression 
and survival in related tauopathies, namely AD, frontotemporal degeneration and 
corticobasal degeneration, are of great importance. Additionally, our study paves the way 
for further functional work assessing the impact of LRRK2 on tau aggregation, and 
exploration of LRRK2 inhibition as a therapeutic approach in patients with tauopathies.  
 
Acknowledgements 
This study was funded by grants from: the Medical Research Council to E.J. (548211); NINDS 
Tau Center without Walls Program (U54-NS100693) to R.R.V., O.A.R. and D.W.D.; the 
Leonard Wolfson Doctoral Training Fellowship in Neurodegeneration to R.H.R.; Alzheimer’s 
Society to R.F.; Parkinson’s UK to M.M.X.T.; the Wellcome Trust (103838), the Cambridge 
Centre for Parkinson-plus and NIHR Cambridge Biomedical Research Centre to J.B.R.; CBD 
Solutions and NIHR Queen Square Biomedical Research Unit in Dementia based at University 
College London Hospitals, University College London to T.R.; the Deutsche 
Forschungsgemeinschaft (DFG, EXC 2145 SyNergy – ID 390857198, HO2402/18-1 
MSAomics), the German Federal Ministry of Education and Research (BMBF, 01KU1403A 
EpiPD; 01EK1605A HitTau), the NOMIS foundation (FTLD project), the German Center for 
Neurodegenerative Diseases (DZNE) to G.U.H.; the Medical Research Council 
(MR/N026004/1), Wellcome Trust (202903/Z/16/Z), Dolby Family Fund and NIHR Biomedical 
Research Centre at University College London Hospitals NHS Foundation Trust and 
University College London to J.H.; anonymous donor to M.S.; the PSP Association to H.R.M. 
The PROSPECT study is supported by grants from the PSP Association, CBD Solutions, the 
MSA Trust, and supported by the National Institute for Health Research University College 
27 
 
London Hospitals Biomedical Research Centre and the Edmond J. Safra Philanthropic 
Foundation. Queen Square Brain Bank is supported by the Reta Lila Weston Institute for 
Neurological Studies and the Medical Research Council. Cambridge Brain Bank is supported 
by the NIHR Cambridge Biomedical Research Centre. The brain bank at Mayo Clinic in 
Jacksonville is supported by CurePSP and the Tau Consortium. This research was supported 
in part by the Intramural Research Program of the National Institutes of Health (National 
Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers: 
ZIA-AG000935, ZIA-NS003154). Tissue samples and clinicopathological information were 
provided by the Johns Hopkins Morris K. Udall Center of Excellence for Parkinson’s disease 
Research (NIH P50 N38377) and the Johns Hopkins Alzheimer Disease Research Center (NIH 
P50 AG05146). This study used the high-performance computational capabilities of the 
Biowulf Linux Cluster at the National Institutes of Health, Bethesda, Maryland, USA 
(http://biowulf.nih.gov). This research was supported in part by the UK Dementia Research 
Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research 
Council, Alzheimer’s Society and Alzheimer’s Research UK. 
 
Author contributions 
E.J. and H.R.M. designed the study. E.J. wrote the manuscript. E.J. and M.S. did the statistical 
analysis and created the figures. All authors were involved in data collection and 
interpretation, and drafting of the manuscript. All authors critically reviewed the manuscript 





Declaration of interests: Miss Tan reports grants from Parkinson's UK, UCL and the Michael 
J Fox Foundation outside the submitted work. Professor Rowe reports grants from the 
Wellcome Trust, the PSP Association and the National Institute for Health Research during 
the conduct of the study; grants from Janssen, Lilly and AZ-Medimmune outside the 
submitted work; personal fees from Asceneuron, Biogen, UCB, WAVE and Astex outside the 
submitted work. Professor Dickson reports grants from the Rainwater Charitable Foundation 
and NIH during the conduct of the study. Professor Höglinger reports grants from the 
German Federal Ministry of Education and Research, Volkswagen Foundation, Lower Saxony 
Ministry for Science and the Petermax-Müller Foundation during the conduct of the study; 
grants from Deutsche Forschungsgemeinschaft, German Federal Ministry of Education and 
Research, NOMIS foundation and EU/EFPIA/Innovative Medicines Initiative outside the 
submitted work; personal fees from Abbvie, Asceneuron, Biogen, Biohaven, Lundbeck, 
Novartis, Roche, Sanofi, UCB, Bayer, Bial, Bristol Myers Squibb, Teva and Zambon outside 
the submitted work. Professor Morris reports grants from the PSP Association and CBD 
Solutions during the conduct of the study; grants from the PSP Association, CBD Solutions, 
Drake Foundation, Parkinson's UK, Cure Parkinson's Trust and the Medical Research Council 
outside the submitted work; personal fees from Teva, Boehringer Ingelheim, GSK, UCB, 
Biogen, Lundbeck and Abbvie outside the submitted work. All of the other authors had 







1. Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of 
frontotemporal lobar degeneration syndromes. Neurology 2016; 86: 1736-1743. 
2. Jabbari E, Holland N, Chelban V, et al. Diagnosis across the spectrum of progressive 
supranuclear palsy and corticobasal syndrome. JAMA Neurol 2020; 77: 377-387. 
3. Jabbari E, Woodside J, Tan MMX, et al. Variation at the TRIM11 locus modifies progressive 
supranuclear palsy phenotype. Ann Neurol 2018; 84: 485-496. 
4. Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy 
and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg 
Psychiatry 2017; 88: 402-411. 
5. Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies 
induce tau inclusions in mouse brain. Proc Natl Acad Sci 2013; 110: 9535-9540. 
6. Mudher A, Colin M, Dujardin S, et al. What is the evidence that tau pathology spreads 
through prion-like propagation? Acta Neuropathol Commun 2017; 5: 99. 
7. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants 
influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43: 699-
705. 
8. Sanchez-Contreras MY, Kouri N, Cook CN, et al. Replication of progressive supranuclear 
palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility 
loci. Mol Neurodegener 2018; 13: 37. 
30 
 
9. Chen JA, Chen Z, Won H, et al. Joint genome-wide association study of progressive 
supranuclear palsy identifies novel susceptibility loci and genetic correlation to 
neurodegenerative diseases. Mol Neurodegener 2018; 13: 41. 
10. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive 
supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet 
Neurol 2014; 13: 676-685. 
11. Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in 
progressive supranuclear palsy. Mov Disord 2014; 29: 470-478. 
12. Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody 
BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple 
ascending dose phase 1b trial. Lancet Neurol 2019; 18: 549-558. 
13. Moss DJH, Pardiñas AF, Langbehn D, et al. Identification of genetic variants associated 
with Huntington’s disease progression: a genome-wide association study. Lancet Neurol 
2017; 16: 701-711. 
14. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive 
supranuclear palsy: The movement disorder society criteria. Mov Disord 2017; 32: 853-864. 
15. Grimm M-J, Respondek G, Stamelou M, et al. How to apply the movement disorder 




16. Blauwendraat C, Faghri F, Pihlstrom L, et al. NeuroChip, an updated version of the 
NeuroX genotyping platform to rapidly screen for variants associated with neurological 
diseases. Neurobiol Aging 2017; 57: e9-e247. 
17. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are 
more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010; 6: 
e1000888. 
18. Li YI, van de Geijn B, Raj A, et al. RNA splicing is a primary link between genetic variation 
and disease. Science 2016; 352: 600-604. 
19. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and 
annotation of genetic associations with FUMA. Nat Commun 2017; 8: 1826. 
20. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between 
pairs of genetic association studies using summary statistics. PLoS Genet 2014; 10: 
e1004383. 
21. Võsa U, Claringbould A, Westra H-J, et al. Unravelling the polygenic architecture of 
complex traits using blood eQTL metaanalysis. bioRxiv 2018; p. 447367. Available from: 
https://www.biorxiv.org/content/10.1101/447367v1. 
22. Wang D, Liu S, Warrell J, et al. Comprehensive functional genomic resource and 
integrative model for the human brain. Science 2018; 362: eaat8464. 
23. Bozdogan H. Model selection and Akaike’s information criterion (AIC): the general 
theory and its analytical extensions. Psychometrika 1987; 52: 345-370. 
32 
 
24. Rohrer JD, Paviour D, Vandrovcova J, Hodges J, de Silva R, Rossor MN. Novel L284R 
MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy 
syndrome. Neurodegener Dis 2011; 8: 149-152. 
25. Iwaki H, Blauwendraat C, Leonard HL, et al. Genetic risk of Parkinson disease and 
progression: An analysis of 13 longitudinal cohorts. Neurol Genet 2019; 5: e348. 
26. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal 
insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide 
association studies. Lancet Neurol 2019; 18: 1091-1102.      
27. de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates 
immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 
2017; 49: 256-261. 
28. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J 
Med 2009; 361: 2609-2618. 
29. Miklossy J, Arai T, Guo J-P, et al. LRRK2 expression in normal and pathologic human brain 
and in human cell lines. J Neuropathol Exp Neurol 2006; 65: 953-963. 
30. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science 2018; 360: 36-37. 
31. Malpetti M, Passamonti L, Jones PS, et al. Neuroinflammation predicts disease 
progression in progressive supranuclear palsy. medRxiv 2020; p. 2020.05.19.20106393v1. 
Available from: https://www.medrxiv.org/content/10.1101/2020.05.19.20106393v1. 
32. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s 
disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51: 296-301. 
33 
 
33. Sanchez-Contreras M, Heckman MG, Tacik P, et al. Study of LRRK2 variation in 
tauopathy: progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2017; 
32: 115-123. 
34. Bardai FH, Ordonez DG, Bailey RM, Hamm M, Lewis J, Feany MB. Lrrk promotes tau 
neurotoxicity through dysregulation of actin and mitochondrial dynamics. PLoS Biol 2018; 
16: e2006265.  
35. Guerreiro PS, Gerhardt E, Lopes da Fonseca T, Bähr M, Outeiro TF, Eckermann K. LRRK2 
Promotes Tau Accumulation, Aggregation and Release. Mol Neurobiol 2016; 53: 3124-3135. 
36. Nguyen APT, Daniel G, Valdés P, Islam MS, Schneider BL, Moore DJ. G2019S LRRK2 
enhances the neuronal transmission of tau in the mouse brain. Hum Mol Genet 2018; 27: 
120-134. 
37. Evans LD, Strano A, Campbell A, et al. Whole genome CRISPR screens identify LRRK2-
regulated endocytosis as a major mechanism for extracellular tau uptake by human 
neurons. bioRxiv 2020; p. 246363. Available from:  
https://www.biorxiv.org/content/10.1101/2020.08.11.246363v1. 
38. Tuck AC, Natarajan KN, Rice GM, et al. Distinctive features of lincRNA gene expression 
suggest widespread RNA-independent functions. Life Sci Alliance 2018; 1: e201800124. 
39. Elkouris M, Kouroupi G, Vourvoukelis A, et al. Long non-coding RNAs associated with 
neurodegeneration-linked genes are reduced in Parkinson’s disease patients. Front Cell 
Neurosci 2019; 13: 58. 
34 
 
40. Zhao Y, Zhao L, Li J, Zhong L. Silencing of long noncoding RNA RP11-476D10.1 enhances 
apoptosis and autophagy while inhibiting proliferation of papillary thyroid carcinoma cells 
via microRNA-138-5p-dependent inhibition of LRRK2. J Cell Physiol 2019; 234: 20980-20991. 
41. Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Mol Degen 
2018; 13: 51. 
42. Maphis N, Xu G, Kokiko-Cochran ON, et al. Reactive microglia drive tau pathology and 
contribute to the spreading of pathological tau in the brain. Brain 2015; 138: 1738-1755. 
43. Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory 
responses. J Neurosci 2012; 32: 1602-1611. 
44. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo 
imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear 
palsy. Mov Disord 2006; 21: 89-93. 
45. Passamonti L, Vazquez-Rodriguez P, Hong YT, et al. [11C]PK11195 binding in Alzheimer 
disease and progressive supranuclear palsy. Neurology 2018; 90: e1989-1996. 
46. Bevan-Jones WR, Cope TE, Jones PS, et al. Neuroinflammation and protein aggregation 
co-localize across the frontotemporal dementia spectrum. Brain 2020; 143: 1010-1026. 
47. van Iperen EPA, Hovingh GK, Asselbergs FW, Zwinderman AH. Extending the use of 
GWAS data by combining data from different genetic platforms. PLoS One 2017; 12: 
e0172082. 
